Nanoparticle-delivered combo boosts cancer immunotherapy
10 April 2017
Cancer cells often evade immune attacks by displaying proteins that disguise them as normal. Checkpoint inhibitors block these proteins and reveal tumor cells to the immune system, but they don't work for many patients. Now University of North Carolina researchers have found that using nanoparticles can boost the efficacy of cancer immunotherapy treatments.
To date 101 inspections for compliance with Russian GMP conducted this year
07 April 2017
Vladislav Shestakov, the Director of the Federal Budget-Funded Institution State Institute for Drugs and Good Practices, presented the results of inspectorate activities, its future plans and spoke about the main amendments to the Federal Law No. 61-FZ “On Circulation of Medicines,”
Russian government allocates 16.1 bln rubles for pharmaceutical industry
07 April 2017
The Decree brings the financing of this state program in line with the Federal Law “On the Federal Budget for 2017 and for the Planning Period of 2018 and 2019.” The budgetary allocations for implementing the program grew by 16.1 billion rubles (from 92.2 billion rubles to 108.3 billion rubles).
06 April 2017
During his confirmation hearing on Wednesday Scott Gottlieb emphasized that he would start his new job as FDA commissioner by focusing on different parts of the agency that have lagged in accelerating drug reviews. With the president beating the table for a streamlined approval process, you can expect some fresh pressure from the top to speed things up. And now Gottlieb — who was already on record on that score — has some additional data to point to for his efficiency campaign, highlighting where the agency has been effective in speeding approvals and where it might push for faster action.
Google's parent company is vacuuming up top talent in health care and biotech
06 April 2017
Alphabet, Google's parent company, is known for its aggressive approach to hiring top computer engineers. Now, it has its sights set on poaching top talent from life sciences and health care.
05 April 2017
In recent years we have seen remarkable scientific breakthroughs in the discovery of new therapies to treat some of the most challenging diseases faced by patients. These groundbreaking medicines have the power to change and save lives, but to help ensure patients have affordable access to these therapies, we need a payment system as innovative as today’s medicines.
Syndax Pharmaceuticals Adds Biopharmaceutical Industry Leader Keith A. Katkin to Board of Directors
04 April 2017
Syndax Pharmaceuticals, Inc. (“Syndax,” the “Company” or “we”) (Nasdaq:SNDX), a clinical stage biopharmaceutical company focused on developing entinostat and SNDX-6352 in multiple cancer indications, today announced the appointment of Keith A. Katkin to its Board of Directors.
04 April 2017
More than half of commercially insured patients’ out-of-pocket spending for brand medicines is based on full list prices, according to a new analysis from Amundsen Consulting, a division of QuintilesIMS. Even though rebates paid by biopharmaceutical companies can substantially reduce the prices insurers and pharmacy benefit managers (PBMs) pay for brand medicines, insurers use list prices—rather than discounted prices—to determine how much to charge patients with deductibles and coinsurance.
Pharma's most-valuable brands? J&J, Pfizer and Merck. Valeant, not so much
04 April 2017
U.S. pharma brands jumped in value almost across the board in Brand Finance's annual look at the nation’s most valuable. The lone exception? Valeant Pharmaceuticals
Cancer Death Rates Continue to Decline
03 April 2017
Overall cancer death rates continue to decrease in men, women, and children for all major racial and ethnic groups, according to the latest Annual Report to the Nation on the Status of Cancer, 1975-2014. The report finds that death rates during the period 2010-2014 decreased for 11 of the 16 most common types of cancer in men and for 13 of the 18 most common types of cancer in women, including lung, colorectal, female breast, and prostate cancers. Meanwhile, death rates increased for cancers of the liver, pancreas, and brain in men and for liver and uterine cancer in women. The report finds overall cancer incidence rates, or rates of new cancers, decreased in men but stabilized in women during the period 1999-2013.
14 March 2024
26 February 2024
NovaMedica team wishes you a Merry Christmas and a Happy New Year!
26 December 2023
Russia and the UAE can simplify the drug registration process
26 April 2024
Big Pharma’s ROI for drug R&D saw 'welcome' rebound in 2023: report
25 April 2024
Orphan drug market to reach $270B by 2028 : Evaluate
25 April 2024
Russian drug for the treatment of viral hepatitis will be exempt from duty in Mongolia
24 April 2024